Company intelligence / Profile preview

Sinedore Medicine Inc.

Taipei, Taipei City, Taiwantw.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Sinedore Medicine Inc. develops a proprietary AI-enabled drug delivery platform for large molecule therapeutics that enables painless administration via oral mucosal, nasal spray, and topical routes. The company’s initial focus is on endocrine and metabolic disorders with pipeline expansion into immune-related and infectious disease areas. No published clinical results or late-stage programs are disclosed as of May 2025.

Therapeutic areas: Metabolic DisordersEndocrinologyImmunologyInfectious Diseases
Modalities: Large molecule drugs (biologics)Non-injectable delivery forms (oral mucosal, nasal spray, topical)
Industry: Biotech

Drug pipeline

6 assets

SD-A05

Preclinical

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Sinedore Medicine Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinedore Medicine Inc..

Explore the full profile